Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Cardiovascular Diseases, Metabolic Syndr...
Phase Not Applicable
Enrollment 7000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review each participant's medical history in a one-on-one interview to assess potential fit for upcoming trials. If needed, the doctor may contact the participant's current doctors or pharmacies to gather more information for eligibility review.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Blood Work — Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.

Primary Outcomes

  • Number of participants who express interest in industry-sponsored clinical research (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-30
Completion: 2030-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 7000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Clindove Research LLC
Principal Investigators:
  • Nelly Cohen, MD (PRINCIPAL_INVESTIGATOR) - Clindove Research LLC
Contact Information
Study Contact:
Nelly Cohen, MD
516-518-3239
study@clindoveresearch.com
Nelly Cohen, MD
516-518-3239
study@clindoveresearch.com
Clindove Research LLC
Nelly Cohen, MD
Clindove Research LLC
Interventions
  • Other: Blood Work — Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.
Study Locations (1 sites)
Clindove Research LLC, Brooklyn, New York 11221 United States
Eligibility Criteria
Inclusion Criteria: * Any participant of age 18 years and over * Who are willing to provide informed consent and participate in the pre-screening study and comply with study procedures. Exclusion Criteria: * Pregnant or breastfeeding individuals * Individuals having severe cognitive impairment or inability to provide informed consent * Individuals having acute psychiatric emergencies requiring immediate intervention/hospitalization * Individuals who are currently participating in another research study that conflicts with pre-screening data collection * Individuals having known history of drug/alcohol misuse * Individuals having medical conditions that, in the investigator's opinion, could compromise the integrity of the screening process or pose significant risks to the participant's health.
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study investigates whether an additional treatment using transcranial magnetic stimulation (TMS) can help severely depressed patients who did not respond well to electroconvulsive therapy (ECT). All participants will first receive standard ECT treatment for depression, including brain scans (fMRI), psychological testing, clinical assessments, and the collection of blood and stool samples. If the ECT treatment is not effective, patients will be invited to participate in a second part of the study where they receive a 4-day course of accelerated TMS (20 sessions in total). The study aims to assess whether this additional TMS treatment can reduce depressive symptoms. The study also explores how brain structure, genetics, and gut health may relate to treatment success. In total, 200 patients will be included.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Transcranial Magnetic Stimulation — TMS is a non-invasive brain stimulation technique

Primary Outcomes

  • Change in Depression Severity - Clinician-Rated (Baseline (within 1 week before first ECT); within 1 week after last ECT session (variable duration); within 1 week after adTMS (20 sessions over 4 days; ECT non-responders only))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitair Ziekenhuis Brussel
Contact Information
Study Contact:
Chris Baeken, MD, PhD
+32 2 477 6801
chris.baeken@uzbrussel.be
Chris Baeken, MD, PhD
+32 2 477 6801
Chris.baeken@uzbrussel.be
UZ Brussel
Sara De Witte, PhD
sara.dewitte@uzbrussel.be
UZ Brussel
Interventions
  • Device: Transcranial Magnetic Stimulation — TMS is a non-invasive brain stimulation technique
Study Locations (1 sites)
UZ Brussel, Jette, Brussels Capital 1090 Belgium
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Major Depressive Disorder (MDD) * Age between 18 - 70 years * Referred for ECT treatment Exclusion Criteria: * A personal history of seizures or epilepsy, a history of seizures or epilepsy in first degree relatives and the presence of any known factor that can lower the seizure threshold (sleep deprivation, abuse substance, etc.), previous head injury and the presence of metallic implants in the cephalic region (e.g., aneurysm clips, shunts, stimulators, cochlear implants, electrodes) except dental fill-ings and the presence of cardiac pacemakers, neurostimulators, surgical clips or other electronic equipment, comorbidity with some neurological disorders: increased intracranial pressure, space-occupying lesion, history of stroke or transient ischemic attack, brain aneurysm and any structural brain damage with increased risk for epilepsy detected with MRI * Patients with cognitive disturbances or dementia (Mini Mental State) \< 24 * Suicide attempt within 6 months before the start of the study or pre-sent risk of suicide per the investigator's clinical judgment
Conditions Depression Disorders, Depression - Major...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This project explores whether heated yoga, sauna, and a mindfulness app reduce depressive symptoms

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: heated yoga — 12-weeks of twice weekly 90-min heated yoga classes in the community
  • Behavioral: sauna — 12-weeks of twice weekly 40-min sauna sessions in the community
  • Behavioral: mindfulness app — 12-weeks of 80-mins a week of a mindfulness app

Primary Outcomes

  • Patient Health Questionnaire (PHQ-9) (Weeks 0, 4, 8, 12, 26, 20)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-12
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Principal Investigators:
  • Maren B Nyer, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Maren B Nyer, PhD
617-726-8895
mnyer@mgh.harvard.edu
Sophie Gower
617 724 1102
sgower@mclean.harvard.edu
Maren B Nyer, PhD
617-726-8895
mnyer@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Behavioral: heated yoga — 12-weeks of twice weekly 90-min heated yoga classes in the community
  • Behavioral: sauna — 12-weeks of twice weekly 40-min sauna sessions in the community
  • Behavioral: mindfulness app — 12-weeks of 80-mins a week of a mindfulness app
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Subject Characteristics Inclusion Criteria: 1. adults (18-65 years old) 2. Ability to provide informed consent 3. English language proficiency 4. PHQ-9 score \> 10, indicating at least moderate depressive symptoms 21 5. Must have filled out the waiver for the community-based partners prior to enrolling in the study\* 6. Individuals of childbearing potential must use an acceptable form of birth control 7. (if applicable) willingness to keep psychiatric medications and psychotherapy stable throughout the course of the study 8. Must be able to access mindfulness app on a device (i.e., smartphone, iPad, etc.) 9. Can travel to Breathe in Harvard Square and at least one Restore location (i.e., Hingham, Somerville, Dedham, Newton, Lynnfield) Exclusion Criteria: 1. Pregnant or planning to become pregnant 2. Breast feeding 3. Active suicidal thinking (i.e., PHQ-9 item 9 ≥1 and a positive response to C-SSRS screener items 3, 4, 5, or 6) 4. Active eating disorders or substance use disorders within the past 12 months, as per the MINI 5. Primary OCD or PTSD, as per the MINI 6. History of bipolar disorder, psychotic disorders, as per the MINI 7. ≥25% drop in PHQ-9 score from screen to baseline 8. Under the influence or withdrawal of drugs or alcohol 9. Positive urine toxicology screen due to illicit drug use or other exclusionary medications. (Potential false positives will be addressed on a case-by-case basis at the discretion of the PI or designee) 10. have had a bone fracture or joint surgery in the past 6 months 11. not able to walk freely or without difficulty 12. any serious, unstable medical condition as determined by the revised Physical Activity Readiness Questionnaire (PAR-Q+) and do not have approval from their treating physician (we will check in with treating physician in the event that participants endorse any item on the PAR-Q+) 13. participants must have a healthcare provider who they could contact if they needed medical care, such as a primary care doctor, a counselor, a psychiatrist, a nurse practitioner, or a clinic that you go to. 14. Significant exposure to heated yoga classes in the past 3 months (i.e., more than 6 classes) 15. Significant exposure to sauna sessions in the past 3 months (i.e., more than 6 sessions) 16. Significant exposure to mindfulness app in the past 3 months (i.e., more than 6 uses of the app) 17. are on medications that make dehydration more likely (e.g., lithium, antipsychotics, insulin-dependent) diuretics, barbiturates, b-blockers, anticholinergics, current ETOH acute intoxication, reduced ability to sweat, hemophilia, pacemaker (magnets used to assemble saunas can interrupt the pacer) 18. antidepressant or psychiatric medications that are initiated less than 8 weeks or a dose change less than 4 weeks prior to screening visit 19. psychotherapy that has been initiated within the past 3 months 20. psychiatric hospitalization within the past year 21. diagnosed with any neurological disorders that would impact participation or make participation unsafe 22. are currently in active ketamine, Electroconvulsive therapy, or Transcranial Magnetic Stimulation treatments 23. are unable to follow the study procedures (e.g., not able to travel to the heated yoga or sauna studios) 24. A subject who in the opinion of the Principal Investigator would not be able to safely complete the study or would jeopardize study integrity
Conditions Metastatic Lobular Breast Carcinoma
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: [68Ga]Ga DOTA-5G — Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.

Primary Outcomes

  • The ability of [68Ga]Ga DOTA-5G PET/CT imaging to detect lesions (2 hours from time of injection)
  • Safety and tolerability of [68Ga]Ga DOTA-5G based on the incidence of adverse events using CTCAE v 5.0 (Up to 7 days from time of injection)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-11-18
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Davis
Collaborators: Dr. Helen K Chew, University of California Davis, Dr. Cameron Foster, University of California Davis, Society of Nuclear Medicine and Molecular Imaging
Principal Investigators:
  • Julie Sutcliffe, PhD (PRINCIPAL_INVESTIGATOR) - University of California, Davis
Contact Information
Study Contact:
Julie Sutcliffe, PhD
916-734-5536
jlsutcliffe@health.ucdavis.edu
Julie L Sutcliffe
916-734-5536
jlsutcliffe@health.ucdavis.edu
University of California Davis
Julie Sutcliffe
University of California Davis
Interventions
  • Drug: [68Ga]Ga DOTA-5G — Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.
Study Locations (1 sites)
University of California Davis, Sacramento, California 95817 United States
Eligibility Criteria
Inclusion Criteria: * (Ability to understand and willingness to sign a written informed consent document. * Men and women age ≥ 18 yrs * Confirmed presence of metastatic/advanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1) or PERCIST * Available archival tumor tissue * Eastern Cooperative Oncology Group Performance Status ≤ 2 * Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells/mm3,Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL. * Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, eGFR \>60 mL/min/1.73m\*2 * Anticipated life expectancy ≥ 3 months * Able to remain motionless for up to 30-60 minutes per scan. Exclusion Criteria: * Pregnant and lactating women * Prisoners * Concurrent malignancy of a different histology that could confound imaging interpretation. * Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)
Conditions Breast Cancer, Breast Adenocarcinoma
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Participation in this study does not prevent you from undergoing surgery in the future.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor — Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions
  • Radiation: Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes — Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions

Primary Outcomes

  • Treatment Safety (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-08
Completion: 2033-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alexander Stessin
Collaborators: Northwell Health
Principal Investigators:
  • Alexander Stessin, MD PhD (PRINCIPAL_INVESTIGATOR) - Stony Brook University Hospital
Contact Information
Study Contact:
Caterina Stony Brook Cancer Center Clinical Trials
631-728-7425
cancerclinicaltrials@sronybrookmedicine.edu
Caterina Vacchi-Suzzi, PhD
6312162993
caterina.vacchi-suzzi@stonybrookmedicine.edu
Cancer Clinical Trials Office
(631)-728-7425
CancerClinicalTrials@stonybrookmedicine.edu
Stony Brook University Cancer Center
Interventions
  • Radiation: Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor — Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions
  • Radiation: Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes — Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions
Study Locations (1 sites)
Stony Brook University Cancer Center, Stony Brook, New York 11794 United States
Eligibility Criteria
Inclusion Criteria: * Biopsy proven invasive carcinoma of the breast, either lobular, ductal and/or no special type * T1-T4, N0-2, M0-1 invasive breast carcinoma by radiological or clinical criteria * Cancer is deemed unresectable, or the patient is a poor surgical candidate as determined following evaluation by a surgeon, or patient declines surgery. * Life expectancy \> 6 months * Negative pregnancy test at the time of start of treatment in any female of reproductive age Exclusion Criteria: * Concurrent systemic therapy (except for endocrine therapy, HER2-targeted therapy, or immunotherapy which are permitted) * Prior radiation to ipsilateral breast or regional nodes * Inability to receive study treatment planning and treatment secondary to body habitus
Conditions Choledocholithiasis With Cholecystitis W...
Phase PHASE2
Enrollment 50
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of this study is to assess the efficacy of the COMBO Endoscopy Oropharyngeal Airway in reducing the incidence of hypoxia in patients undergoing ERCP under sedation.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: The COMBO Endoscopy Oropharyngeal Airway — Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.

Primary Outcomes

  • The incidence of hypoxia (Patients will be followed for the duration of hospital stay, an expected average about 2 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-06-12
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang University
Contact Information
Study Contact:
DiSan Head of Anesthesiology, PhD
86+18616514088
184872238@qq.com
Lianjuan Sun, Master
+8618257152767
sunlianjuan26@163.com
DiSan Diansan Su, PhD
86+18616514088
184872238@qq.com
he First Affiliated Hospital, Zhejiang University School of Medicine
Interventions
  • Device: The COMBO Endoscopy Oropharyngeal Airway — Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
Study Locations (2 sites)
he First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000 China
The First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years; * The ASA classification ranges from I to III. * Patients have signed the informed consent form. * Patients scheduled to undergo sedated ERCP examination; * The estimated duration of the procedure does not exceed 45 minutes. Exclusion Criteria: 1. Patients with coagulation disorders, tendency for oral/nasal bleeding, mucosal injury/occupying lesions, or difficult oropharyngeal airway insertion making airway management unfeasible; 2. Severe cardiac dysfunction (\<4 METs); 3. Severe renal insufficiency (requiring preoperative dialysis); 4. Child-Pugh class C; 5. Diagnosed chronic obstructive pulmonary disease (COPD) or other acute/chronic pulmonary diseases requiring long-term/intermittent oxygen therapy; 6. Increased intracranial pressure; 7. Upper respiratory tract infections (oral/nasal/pharyngeal); 8. Fever (core temperature \>37.5°C); 9. Confirmed pregnancy or current breastfeeding; 10. Allergy to sedatives (e.g., propofol) or medical adhesives; 11. Emergency procedures; 12. Multiple trauma injuries; 13. Peripheral oxygen saturation (SpO2) levels below 95% while breathing room air preoperatively; 14. BMI \<18.5 or \>30 kg/m²; 15. Current participation in other clinical trials; 16. Other conditions deemed ineligible by investigators.
Conditions Radiomic, Radiomics, Breast Cancer Metas...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Drug: Trastuzumab deruxtecan (DS-8201a) — A subgroup of the study cohort treated with Trastuzumab Deruxtecan in the metastatic setting

Primary Outcomes

  • HER2 protein expression (Time of the metastatic biopsy (through study completion, an average of 1 year))
  • Progression-Free Survival (From treatment start to disease progression or death (through study completion, up to 5 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-01
Completion: 2027-01-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact Information
Study Contact:
Claudio Vernieri, MD, PhD
+390223903066
claudio.vernieri@istitutotumori.mi.it
Leonardo Provenzano, MD
+390223903066
leonardo.provenzano@istitutotumori.mi.it
Interventions
  • Drug: Trastuzumab deruxtecan (DS-8201a) — A subgroup of the study cohort treated with Trastuzumab Deruxtecan in the metastatic setting
Study Locations (1 sites)
Fondazione IRCCS Istituto Nazionale Tumori, Milan, 20133 Italy
Eligibility Criteria
Inclusion Criteria: * Patients with metastatic breast cancer underwent a liver, lung, pleural or bone biopsy in the metastatic setting, performed from 01Jan2005 to 01Jan2024. Exclusion Criteria: * Not available imaging (CT scan and/or PET-FdG scan) in the three months before the biopsy or before the last previous treatment interruption; * Unknown HER2 status; * Node, soft tissue or other visceral as biopsy site.
Conditions Hereditary Breast and Ovarian Cancer Syn...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Ovarian cancer is the gynecological malignancy with the highest fatality rate, seriously threatening the life and health of women. One of the main reasons for its high fatality rate is that approximately 70% of patients are diagnosed at an advanced stage. Fortunately, about 1/5 of ovarian cancers are associated with genetic factors, providing us with an opportunity to screen high-risk populations and thereby prevent and diagnose the disease at an early stage and reduce the disease burden. Currently, research related to hereditary ovarian cancer in China is still very scarce, and clinical practice relies on data from foreign studies. However, hereditary tumors have distinct regional and ethnic characteristics, making it urgent to conduct clinical research based on the Chinese population to guide clinical practice in China. Current research suggests that approximately 50% - 60% of hereditary ovarian cancers are closely related to the BRCA1/2 genes. Therefore, accurately assessing the risk of ovarian cancer in BRCA1/2 germline mutation carriers is of great significance for the prevention and treatment of hereditary ovarian cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Procedure: risk-reducing salpingo-oophorectomy (RRSO) — The proportion of BRCA1/2 germline mutation carriers in the high-risk population of ovarian cancer who undergo risk-reducing salpingo-oophorectomy (RRSO). RRSO refers to the preventive surgical removal of both fallopian tubes and ovaries to reduce the risk of ovarian cancer, fallopian tube cancer, and peritoneal cancer.

Primary Outcomes

  • The age at which pathologically diagnosed with ovarian malignant tumors (ICD-10 C56) (From enrollment to the end of follow-up at 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2016-01-01
Completion: 2035-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University Third Hospital
Contact Information
Study Contact:
Yuan Li
18610689868
yuanli@bjmu.edu.cn
Hong
010-82266699
bysy@bjmu.edu.cn
Peking University Third Hospital
Interventions
  • Procedure: risk-reducing salpingo-oophorectomy (RRSO) — The proportion of BRCA1/2 germline mutation carriers in the high-risk population of ovarian cancer who undergo risk-reducing salpingo-oophorectomy (RRSO). RRSO refers to the preventive surgical removal of both fallopian tubes and ovaries to reduce the risk of ovarian cancer, fallopian tube cancer, and peritoneal cancer.
Study Locations (1 sites)
Peking University Third Hospital, Beijing, Beijing Municipality 100191 China
Eligibility Criteria
Inclusion Criteria: * Pathologically diagnosed with ovarian malignant tumor. * Identified as carriers of BRCA1/2 germline pathogenic or likely pathogenic mutations through genetic testing, in accordance with the "Standards and Guidelines for the Interpretation of Sequence Variants" (2015 Edition) of the American College of Medical Genetics and Genomics (ACMG). * Age of 18 years or older. ④ Voluntary participation in this research and signing of the informed consent form. Exclusion Criteria: * ① Patients who refuse to provide necessary information.
Conditions Bipolar Disorder (BD), Major Depressive ...
Phase NA
Enrollment 623
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this interventional clinical trial is to assess the diagnostic performance of a composite diagnostic medical devise based on blood-based in vitro diagnostic device and Mood Disorder Questionnaire (MDQ) in identifying bipolar disorder among adult patients presenting with a current major depressive episode in primary care. The study will compare the results of the medical device diagnostic test to those of standardized psychiatric clinical evaluation, to evaluate its sensitivity, specificity, and overall clinical utility. The main research questions are : * Can the investigational medical device accurately distinguish bipolar disorder from unipolar depression ? * How does its diagnostic accuracy compare with validated psychiatric questionnaires commonly used in clinical practice ? Participants will : * Provide a blood sample for biomarker analysis using the investigational diagnostic device. * Complete a few validated psychiatric assessment tools (e.g., MDQ, MINI). * Share sociodemographic and clinical data relevant to psychiatric evaluation.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Venous blood sample for measuring blood biomarkers related to bipolar disorder — Participants will undergo a venous blood draw for analysis by an investigational composite medical device designed to aid in the diagnosis of bipolar disorder. The device analyzes specific circulating biomarkers hypothesized to differ between patients with bipolar disorder and those with unipolar depression.
  • Other: Standardized psychiatric assessment tools — Participants will complete validated psychiatric screening tools used as reference standards to evaluate bipolar disorder, including the Mood Disorder Questionnaire (MDQ). These tools will be used to compare their diagnostic output with that of the investigational blood test.

Primary Outcomes

  • Sensitivity and specificity of the composite medical device, using the full clinical evaluation as a reference (Through study completion, an 8 weeks follow-up for each patient)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-30
Completion: 2028-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 623 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Montpellier
Collaborators: CH Béziers, Centre Hospitalier Universitaire de Nīmes, Assistance Publique Hopitaux De Marseille, University Hospital, Toulouse, Nantes University Hospital, USSAP Carcassonne, Ajaccio Hospital Center, CH TOULON, CH Thuir, CH Montauban, Centre de Ressources Biologiques de Montpellier, Federation Regionale de Recherche en Psychiatrie et Sante Mentale Occitanie
Contact Information
Study Contact:
Raoul BELZEAUX
+33 0467337913
raoul.belzeaux@chu-montpellier.fr
Raoul BELZEAUX
+330467337913
raoul.belzeaux@chu-montpellier.fr
CHU de Montpellier
Interventions
  • Diagnostic Test: Venous blood sample for measuring blood biomarkers related to bipolar disorder — Participants will undergo a venous blood draw for analysis by an investigational composite medical device designed to aid in the diagnosis of bipolar disorder. The device analyzes specific circulating biomarkers hypothesized to differ between patients with bipolar disorder and those with unipolar depression.
  • Other: Standardized psychiatric assessment tools — Participants will complete validated psychiatric screening tools used as reference standards to evaluate bipolar disorder, including the Mood Disorder Questionnaire (MDQ). These tools will be used to compare their diagnostic output with that of the investigational blood test.
Study Locations (1 sites)
CHU de Montpellier, Montpellier, 34090 France
Eligibility Criteria
Inclusion Criteria : * Cis man, cis woman, trans man, trans woman or non-binary, * Aged 18 to 65 years old, * Meets the DSM-5 criteria for the diagnosis of moderate to severe EDC and is eligible for antidepressant treatment. Non-Inclusion Criteria : * Patients under guardianship or trusteeship, * Patients with schizophrenia according to DSM-5 criteria, * Patients who have received psychotropic treatment in the 5 days prior to inclusion (or 21 days for fluoxetine or aripiprazole), with the exception of benzodiazepines and hydroxyzine at the doses and in compliance with the indications of the Marketing Authorisations, * Patients with an unstable physiological state or a serious and symptomatic medical condition in the opinion of the investigator, * Pregnant or breast-feeding patients, * Patients with a known autoimmune disease, in particular Crohn's disease or thyroiditis, or any other pathology which could, in the opinion of the investigator, modify the blood concentration of immune biomarkers, * Patients unable to give informed consent to participate in the study or who cannot be given informed information, * Patients not covered by a social security scheme, * Patients participating in another interventional study on the day of inclusion, * Patients under court protection, * Patients vaccinated less than 30 days ago, * Patients with difficulties reading, understanding or speaking French. Exclusion Criteria : * Participants will have the right to withdraw their consent at any time for any reason whatsoever without any prejudice to them, * The investigator may prematurely exclude a subject from the study, in agreement with the sponsor, if the subject presents one or more exclusion criteria, * Diagnosis of schizophrenia during follow-up or any other diagnosis that would lead to a change in the initial EDC diagnosis, * Any condition or situation which, in the opinion of the investigator, would be incompatible with the continuation of the study or which would lead to a bias in the management of the data.
Conditions Uncontrolled Hypertension
Phase PHASE1
Enrollment 82
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: SAL0140 — In this part, SAL0140 tablets will be administered as a single or multiple oral dose.
  • Drug: SAL0140 placebo — In this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.

Primary Outcomes

  • The rate of Adverse events (from Day 1 to Day8 or Day23 or Day28)
  • The rate of normality or abnormality of electrocardiogram (from Day 1 to Day8 or Day23 or Day28)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-06-09
Completion: 2026-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 82 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Principal Investigators:
  • Chongyuan Xu, Ph.D (PRINCIPAL_INVESTIGATOR) - Nanfang Hospital, Southern Medical University
Contact Information
Study Contact:
Chongyuan Xu, Ph.D.
13926186470
nflcyljd@smu.edu.cn
Chongyuan Xu, Ph.D
13926186470
nflcyljd@smu.edu.cn
Nanfang Hospital of Southern Medical University
Chongyuan Xu, Ph.D
Nanfang Hospital of Southern Medical University
Interventions
  • Drug: SAL0140 — In this part, SAL0140 tablets will be administered as a single or multiple oral dose.
  • Drug: SAL0140 placebo — In this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.
Study Locations (1 sites)
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong 510515 China
Eligibility Criteria
Inclusion Criteria: * Subjects has fully understood and voluntarily signed the informed consent form, and is able to comply with the requirements and restrictions listed in the informed consent form; * Male or female aged 18-65 years (including 18 and 65 years old); * Male body weight ≥50kg, female body weight ≥45kg and body mass index (BMI) between 19.0 - 26.0 kg/m2 (including 19.0 and 26.0, BMI = weight(kg) / height(cm)2) at screening; * All examinations (including physical examination, vital signs, laboratory tests, ECG, chest X-ray (anterior and lateral views), etc.) show no abnormalities or minor abnormalities deemed non clinical signiant by the investigator; Exclusion Criteria: * Subjects with orthostatic tachycardia or orthostatic hypotension at screening; or those with a history of orthostatic hypotension symptoms (such as dizziness, fatigue, blurred vision, pallor upon standing) or orthostatic tachycardia symptoms (such as dizziness, palpitations, tremors, general weakness, blurred vision, exercise intolerance when standing); * Subjects have used corticosteroids within 3 months prior to dosing; * Subjects with personal or family history of long QT syndrome, torsades de pointes, or other complex arrhythmias, or family history of sudden death; * Subjects with prolonged QTcF interval (\>450msec) on ECG; * Subjects with potassium levels above the upper limit of normal (\>ULN) or sodium levels below the lower limit of normal (\<LLN) in biochemistry tests; * Subjects with known allergies to excipients in the study drug or history of severe allergic reactions (including food, drugs, insect bites, etc.); * Subjects with any disease history or current condition that may affect the safety evaluation or drug disposition of the study participant, including but not limited to central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, immune system, psychiatric conditions, metabolic disorders, gastrointestinal surgery (except appendectomy), etc.; * Subjects have undergone gastric surgery, vagotomy, bowel resection, or any surgery that may interfere with gastrointestinal motility, pH, or absorption; * Subjects received live or attenuated vaccines within 4 weeks prior to screening; * Subjects consume excessive tea, coffee, and/or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) daily, or have consumed these beverages within 48h prior to dosing, or cannot stop consuming during the trial; * Subjects have taken any prescription drugs, over-the-counter medications, Chinese herbs, or dietary supplements (including vitamins, health foods, etc.) within 14 days prior to dosing; * Subjects with a history of long-term consumption of xanthine-rich or grapefruit-containing beverages or foods, or who have consumed any xanthine-rich or grapefruit products within 48h prior to dosing; * Subjects have smoked within 3 months prior to screening, or cannot stop using any tobacco products during the trial; * Subjects have participated in other clinical trials and taken any investigational drugs within 3 months prior to screening; * Subjects have donated blood or lost blood ≥400 mL, received blood transfusion or blood products within 3 months prior to screening; * Subjects have had unprotected sexual intercourse within 2 weeks prior to screening; study participants and their spouses or partners who have pregnancy plans, sperm/egg donation plans during the study period until 1 month after dosing, or do not agree to use at least one of the following acceptable effective contraception methods: * Correctly placed intrauterine device; * Male/female condom used in combination with topical spermicide (i.e., foam, gel, film, cream, or suppository); * Male vasectomy or vas deferens ligation; * Female bilateral tubal ligation/bilateral salpingectomy or bilateral tubal occlusion surgery (occlusion surgery verified effective by relevant instruments); * Abstinence. * Pregnant or lactating women, or women of childbearing potential with positive pregnancy screening results; * Subjects are alcoholic or regular drinkers within 3 months prior to screening, i.e., weekly alcohol consumption exceeding 14 standard units (1 unit = 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine) or positive baseline alcohol breath test, or cannot stop using any alcohol-containing products during the trial; * Subjects positive drug abuse screening or history of drug abuse or previous use of illicit drugs; * Subjects tested positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, or human immunodeficiency virus (HIV) antibody; Subjects deemed by the investigator to have poor compliance or other factors that unsuitable for participation in this trial.
Conditions Hypertension, Aging, Exercise
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

BACKGROUND: Physical exercise promotion is one of the main global goals of innumerous health and medical societies for preventing and managing noncommunicable chronic diseases (NCDs), being one of the main therapeutic for the patient with hypertension. Exercise in heated swimming pool has emerged as a potential alternative to physical exercise on the ground for the reduction of blood pressure (BP) of hypertensive patients, however, its effects on BP, as well as hemodynamic, metabolic, inflammatory and functional variables of older individuals with hypertension have not been investigated. PURPOSE: To evaluate the effects of heated water-based exercise (HEx) versus land-based exercise (LEx) on BP, arterial stiffness, endothelial function, metabolic, inflammatory and functional variables of older individuals with hypertension. METHODS: 60 older individuals (male and female) with hypertension (age \> 60 years) will be randomized in 2:2:1 ratio to HEx, LEx or control (CON) intervention. The feasibility and physiological adaptations (physical capacity, musculoskeletal and cardiovascular responses to stress, biological and biochemical markers associated with the pathophysiology of the disease and vascular adaptations) will be assessed before, after 12 weeks and after 24 weeks of follow-up. HEx and LEx training programs will be performed three times per week and will be performed for the firs 12 weeks of follow-up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Physical Exercise Session in heated Swimming Pool - HEx — Warm Up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise (following the same control parameter of the experimental session); Resistance exercises - 20 minutes of resisted exercises, which will be divided into 6 exercises with 2 sets of 10 to 15 repetitions (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
  • Other: Physical Exercise Session in Land- LEx — Warm up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise performed on treadmill and / or exercise bike (following the same control parameter of the experimental session); Endurance Exercises - 20 minutes of exercises resisted, also divided into 6 exercises with 2 sets of 10 to 15 repetitions. The large muscle groups of the upper limbs, lower limbs and trunk will be exercised in fitness machine and with free weights (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
  • Other: Control Session Without Exercise- CON — Guidance to maintain the usual level of physical activity and not to enter physical exercise programs during the 12 weeks of follow-up.

Primary Outcomes

  • Blood pressure change (baseline, 3 month and 6 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-08-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidade Estadual Paulista Júlio de Mesquita Filho
Collaborators: Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Contact Information
Study Contact:
Awassi Y. Ngomane, Master
+5511985678113
awassiyn@gmail.com
Awassi Y. Ngomane, Master
+5511985678113
awassiyn@gmail.com
Universidade Estadual Paulista Julio de Mesquita Filho
Emmanuel G. Ciolac, Doctor
+551114 982181511
emmanuel.ciolac@unesp.br
Universidade Estadual Paulista Julio de Mesquita Filho
Interventions
  • Other: Physical Exercise Session in heated Swimming Pool - HEx — Warm Up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise (following the same control parameter of the experimental session); Resistance exercises - 20 minutes of resisted exercises, which will be divided into 6 exercises with 2 sets of 10 to 15 repetitions (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
  • Other: Physical Exercise Session in Land- LEx — Warm up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise performed on treadmill and / or exercise bike (following the same control parameter of the experimental session); Endurance Exercises - 20 minutes of exercises resisted, also divided into 6 exercises with 2 sets of 10 to 15 repetitions. The large muscle groups of the upper limbs, lower limbs and trunk will be exercised in fitness machine and with free weights (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
  • Other: Control Session Without Exercise- CON — Guidance to maintain the usual level of physical activity and not to enter physical exercise programs during the 12 weeks of follow-up.
Study Locations (1 sites)
Universidade Estadual Paulista Julio de Mesquita Filho, Bauru, São Paulo 17033-360 Brazil
Eligibility Criteria
Inclusion Criteria: \- For the study population, the following will not be included in the study: * Smokers (avoiding acute effects of smoking on physiological measures); * Individuals with decompensated cardiovascular disease, thyroid dysfunction and / or inflammatory diseases; * Unable individuals to perform an exercise program or ergospirometric test due to physical or mental incapacity; * Individuals with hemodynamic and / or electrocardiographic changes during the ergospirometric test. * Only individuals older than 60 years, with a diagnosis of SAH for more than 6 months (stage 1 or 2), using antihypertensive medication (office BP less than 140/90 mmHg) and without medication change for at least 2 months. Exclusion Criteria: * For the study population, individuals who have less than 60% adherence to scheduled physical exercise sessions will be excluded during the study. * Individuals who change or discontinue their clinical and / or pharmacological treatment (with or without a prescription).
Conditions Prostate Cancer Castration-resistant Pro...
Phase PHASE1, PHASE2
Enrollment 150
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ADC — MBRC-201 ADC

Primary Outcomes

  • Type, incidence, severity, seriousness, and relatedness of adverse events (AEs) (From Enrollment through treatment and long term follow-up (approximately 24 months))
  • • Incidence and prevalence of Dose-limiting Toxicities (DLTs) and cumulative safety by dose level (21 days)
  • Duration of Response (DOR) (Approximately 24 months)
  • Disease Control Rate (DCR) (Approximately 24 months)
  • Progression Free Survival (PFS) (Approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-09-03
Completion: 2029-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MBrace Therapeutics
Contact Information
Study Contact:
Lam Phu
415-613-2945
Phu.Lam@ucsf.edu
UCSF Helen Diller Family Comprehensive Cancer Center
Rauhl Aggarwal, MD
UCSF Helen Diller Family Comprehensive Cancer Center
Manish R Sharma, MD
6163891824
abigail.vankirk@startresearch.com
START, Midwest
Interventions
  • Drug: ADC — MBRC-201 ADC
Study Locations (7 sites)
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94158 United States
START, Midwest, Grand Rapids, Michigan 49546 United States
START, Astera, East Brunswick, New Jersey 08816 United States
NEXT, Dallas, Irving, Texas 75039 United States
START San Antonio, San Antonio, Texas 78229 United States
START, Mountain Region, West Valley City, Utah 84119 United States
NEXT, Virginia, Fairfax, Virginia 22031 United States
Eligibility Criteria
Inclusion Criteria: Patients are eligible to be included in the study only if all of the following criteria apply: 1. Provide written consent on an informed consent form (ICF), approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific evaluation. Patients should have the ability to read and understand the ICF, ask for any clarifications from the study staff, and be able to comply with all planned study procedures. 2. 18 years of age or older at the time of informed consent. 3. Female patients must be at least 2 years postmenopausal (defined as 2 years without menses), surgically sterile (at least 6 months prior to dosing; must be documented) or patients of childbearing potential under the following conditions: * Must be nonlactating and have a negative serum (preferred) or urine pregnancy test results within 72 hours prior to the first dose of MBRC-201. * Must agree not to try to become pregnant during the study and for at least 6 months after the final dose of MBRC-201 * Must agree to practice effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) and willing to continue to use effective contraception for the duration of study participation and for 6 months after the final dose of study drug. 4. Male patients whose partners are of childbearing potential must agree to use effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) (Section 10.4) for the duration of study participation and for 6 months after the final dose of study drug. 5. Have a histologic or cytologic diagnosis of malignant solid tumor for which there are no standard-of-care treatment options known to confer a clinical benefit or for which the patient is ineligible or declines (except for Phase 1b-Cohort A). A. For Phase 1a dose escalation: Patients must have one of the following tumor types: i. mCRPC, breast cancer (TNBC, HR+/HER2-negative or HER2-low, HR-/HER2+), CRC, NSCLC, or PDAC B. For Phase 1b: Patients must have one of the following tumor types: i. Cohort A: Histologic or cytologic diagnosis of mCRPC (with confirmed adenocarcinoma histology) refractory to standard treatment. Patients must have had prior exposure to at least one novel AR-targeted therapy (e.g., abiraterone acetate, enzalutamide, apalutamide, darolutamide). Prior taxane or lutetium Lu 177 vipivotide tetraxetan is acceptable but not required. ii. Cohort B: Histologic or cytologic diagnosis of advanced metastatic NSCLC refractory to standard treatment. iii. Cohort C: Histologic or cytologic diagnosis of advanced metastatic breast cancer (TNBC, HR+/HER2-negative or HER2-low, HR-/HER2+) refractory to standard treatment. iv. Cohort D: Histologic or cytologic diagnosis of advanced metastatic CRC, PDAC refractory to standard treatment. The Sponsor may add or remove specific tumor indications based on emerging, real-time study results. 6. Availability of a tumor tissue sample (formalin-fixed paraffin-embedded \[FFPE\]) must be confirmed if feasible. Patients without tumor sample may be eligible with medical monitor approval. Tumor biopsies are not required and should not be performed to assess eligibility. 7. For Dose Escalation (Phase 1a), patients may have evaluable disease or measurable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1. For both Dose Expansion (Phase 1b) and Phase 2, patients must have measurable disease according to RECIST v1.1 8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. 9. Life expectancy ≥ 3 months 10. Patient must have adequate organ and marrow function as defined below. * Absolute neutrophil count (ANC) ≥ 1500/uL * Hemoglobin (Hgb) ≥ 9 g/dL * Platelet count ≥ 100,000/uL * International normalized ratio (INR) \< 1.5 (or ≤ 3.0 if on therapeutic anticoagulation) * Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min by the CKD-EPI or similar equation or as measured by 24-hour urine collection * Total bilirubin ≤ 1.5 × ULN \[or ≤ 3-times ULN for patients with Gilbert's disease or documented hepatic tumor involvement\] * ALT and AST ≤ 3 × ULN \[or ≤ 5-times ULN for patients with documented hepatic tumor involvement\] Exclusion Criteria: Patients are excluded from the study if any of the following criteria apply: 1. History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Allowed exceptions are patients with: 1. Non-melanoma skin cancer considered completely cured; 2. Localized prostate cancer treated with curative intent with no evidence of progression; 3. Low-risk or very low-risk (per standard clinical guidelines) localized prostate cancer under active surveillance without immediate intent to treat; 4. Malignancy that is otherwise considered cured with minimal risk of recurrence. 2. Known or suspected sensitivity to any of the ingredients of the investigational product MBRC-201. 3. Active cerebral/meningeal disease related to the underlying malignancy. Patients with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the patient is clinically stable. (defined as not having received steroid treatment for symptoms related to cerebral/meningeal disease for at least 2 weeks prior to the first dose of study drug and with no ongoing related AEs). 4. Any uncontrolled viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug, unless deemed not clinically significant by the investigator (e.g., onychomycosis). Routine antimicrobial prophylaxis is permitted. 5. Active or symptomatic viral hepatitis, including patients with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months). Patients who have been treated for hepatitis C infection or who have spontaneously recovered are permitted. 6. Patients with HIV infection with 1 or more of the following: * Acquired immunodeficiency syndrome (AIDs)-defining opportunistic infection within 6 months of the start of screening * A change in antiretroviral therapy within 3 months of the start of screening and viral load \> 500 copies/mL * Receiving antiretroviral therapy that may interfere with study drug * CD4 count \< 350 at screening 7. Thromboembolic events and/or bleeding disorders ≤ 14 days (e.g., venous thromboembolism \[VTE\] or pulmonary embolism \[or PE\]) prior to the first dose of study drug 8. Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug 9. A baseline QT (time from the beginning of the Q wave to the end of the T wave) interval as corrected by Fridericia's formula (QTcF) \> 470 msec or patients with risk factors for Torsades de pointes 10. Uncontrolled Inflammatory Bowel Disease (IBD) 11. A history of (non-infectious) ILD/pneumonitis requiring steroid therapy, or active ILD/pneumonitis, or clinically suspected ILD/pneumonitis that cannot be ruled out by imaging at screening 12. Uncontrolled autoimmune disease or syndrome 13. Active ocular surface disease at screening, including confluent superficial keratitis, cornea epithelial defect, corneal ulcer or stromal opacity or any components of the ophthalmologic history which, in the investigator's opinion, may place the patient at significant risk. Cataracts alone are not an exclusion criterion. 14. Any anticancer therapy within 14 days prior to the first dose of study drug, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy,